10-Q is out. There is anticipation for the transi
Post# of 212
Posted On: 11/05/2013 6:20:50 AM
10-Q is out.
There is anticipation for the transition into Canada. With the 10-Q out early this week could see some interesting developments. $$$ moving forward in any bio is a concern, Sunshine is no exception. When the ink is on the paper in front of prospective and current shareholders for funding then we'll have something to chew on. As for institutional investors , imo they won't be in the picture until the IND is on the street with the FDA ~ and then they may want to wait further into the trials. If they're interested in a buy out they would want to hold back putting in their $$$. Why raise the price yourself on something your getting ready to buy? Still, I wouldn’t expect to see interest from the big pharmas or big $$ until trials start. Getting a deal from a big private pharma or fund is certainly not out of the question. Sunshine will need about $5M just to get rolling. I don’t see that as being a problem but I’d like to see them get $10M.
Keep this in mind, since inception, the cost is only $4.8M. For everything they've accomplished to date and only showing about $4.8M in debt ? To me that shows excellent management and control. For a drug that has some pretty decent potential and a pipeline with impressive growth potential. Some of us have been projecting when we would see the IND. Adva-27a is expected to enter Phase I clinical trials for multidrug resistant breast cancer in mid to late 2014 . That puts pijoe and my guess pretty much on the mark for end of 1st quarter to mid second quarter . My guess was more to the end of 1st quarter. 30 days after IND right into clinicals. The list of what needs to be done is in the filing.
Yes, Camille does answer his phone, almost 24-7. I imagine this week and the next couple weeks will be very busy for them. I am looking forward to seeing what Sunshine has been up to behind the scenes. With the 10-q out already they should be able to finish up the incorp move.
http://www.sec.gov/Archives/edgar/data/140232...fm_10q.htm
Keep this in mind, since inception, the cost is only $4.8M. For everything they've accomplished to date and only showing about $4.8M in debt ? To me that shows excellent management and control. For a drug that has some pretty decent potential and a pipeline with impressive growth potential. Some of us have been projecting when we would see the IND. Adva-27a is expected to enter Phase I clinical trials for multidrug resistant breast cancer in mid to late 2014 . That puts pijoe and my guess pretty much on the mark for end of 1st quarter to mid second quarter . My guess was more to the end of 1st quarter. 30 days after IND right into clinicals. The list of what needs to be done is in the filing.
Yes, Camille does answer his phone, almost 24-7. I imagine this week and the next couple weeks will be very busy for them. I am looking forward to seeing what Sunshine has been up to behind the scenes. With the 10-q out already they should be able to finish up the incorp move.
http://www.sec.gov/Archives/edgar/data/140232...fm_10q.htm
(0)
(0)